HomeNewsBusinessHUL yet to decide on restarting operations at 3 manufacturing plants that saw COVID cases

HUL yet to decide on restarting operations at 3 manufacturing plants that saw COVID cases

The three manufacturing plants are located at Haridwar in Uttarakhand, South of India (erstwhile GSK plant) and in West Bengal.

July 21, 2020 / 21:18 IST
Story continues below Advertisement

Hindustan Unilever, India’s largest FMCG firm that shut its three manufacturing plants due to COVID positive cases is yet to decide when operations will resume at these plants.

In a media call post the announcement of April-June results, Sanjiv Mehta Chairman and Managing Director said, “We are following all operation standards of hygiene. We are going for extensive testing of all employees of these 3 factories.”

Story continues below Advertisement

The three manufacturing plants are located at Haridwar in Uttarakhand, South of India (erstwhile GSK plant), and in West Bengal.

“The total employee strength of these factories is around 5,000 employees and only a small percentage of employees were tested positive," Mehta said, adding that of this 80-85% of employees were asymptomatic. As an added precaution, HUL decided to close the site to ensure deep cleaning and sanitisation before restarting operations.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show